p27 in FLT3-driven acute myeloid leukemia: many roads lead to ruin.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

1. Overexpression of TREM1 predicts poor prognosis and chemotherapy resistance in Egyptian acute myeloid leukemia associated with FLT3 internal tandem duplication and CD123 expression and stemness signatures.Discover oncology · 2026
   Article
2. CDK6 Inhibition: A Novel Approach in AML Management.International journal of molecular sciences · 2020
   Review
3. Role of alternative polyadenylation dynamics in acute myeloid leukaemia at single-cell resolution.RNA biology · 2019
   Article

Corrections and comments

• Comment on
  FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p272017

Authors and funding

3 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as